OPKO HEALTH, INC.
OPKOPKO Health, Inc. is a medical test and medication company focused on diagnostics and pharmaceuticals. The company is a publicly traded company on NASDAQ and TASE under the symbol "OPK".
Drugs in Pipeline
18
Phase 3 Programs
6
Upcoming Catalysts
1
Next Catalyst
Jul 30, 2026
5wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
Somatropin
Pediatric Growth Hormone Deficiency
MOD-4023
Pediatric Growth Hormone Deficiency
CTAP101 30 μg capsules
Chronic Kidney Disease
Genotropin
Growth Hormone Deficiency
CTAP101 Capsules
Chronic Kidney Disease
Cohort 1 CTAP101 Capsules- 60µg
Chronic Kidney Disease
CTA018 cream
Psoriasis
Rayaldee
COVID-19
MDX2003
Lymphoma
MDX2004
Advanced Tumors
MDX2001
Biliary Tract Cancer
LY2944876
Diabetes Mellitus, Type 2
CTA018 Injection
Chronic Kidney Disease
TT223 with Metformin and/or TZD
Diabetes Mellitus, Type 2
OPK-88003
Type 2 Diabetes Mellitus
ELND005 (scyllo-inositol)
Alzheimer's Disease
ELND005
Alzheimer's Disease
bevasiranib
Diabetic Macular Edema
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Somatropin | Phase 3 | Pediatric Growth Hormone Deficiency | - | - |
MOD-4023 | Phase 3 | Pediatric Growth Hormone Deficiency | - | - |
CTAP101 30 μg capsules | Phase 3 | Chronic Kidney Disease | - | - |
Genotropin | Phase 3 | Growth Hormone Deficiency | - | - |
CTAP101 Capsules | Phase 3 | Chronic Kidney Disease | - | - |
Cohort 1 CTAP101 Capsules- 60µg | Phase 3 | Chronic Kidney Disease | - | - |
CTA018 cream | Phase 2 | Psoriasis | - | - |
Rayaldee | Phase 2 | COVID-19 | - | - |
MDX2003 | Phase 2 | Lymphoma | - | - |
MDX2004 | Phase 2 | Advanced Tumors | - | - |
MDX2001 | Phase 2 | Biliary Tract Cancer | - | - |
LY2944876 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
CTA018 Injection | Phase 2 | Chronic Kidney Disease | - | - |
TT223 with Metformin and/or TZD | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
OPK-88003 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
ELND005 (scyllo-inositol) | Phase 2 | Alzheimer's Disease | - | - |
ELND005 | Phase 2 | Alzheimer's Disease | - | - |
bevasiranib | Phase 2 | Diabetic Macular Edema | - | - |